Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Mendonca-de-Pontes, R. (Robéria) | - |
dc.creator | Montero, J. (Juan) | - |
dc.creator | Sanoja-Flores, L. (L.) | - |
dc.creator | Puig, N. (Noemí) | - |
dc.creator | Pessoa-de-Magalhaes, R.J. (Roberto J.) | - |
dc.creator | Corral-Mateos, A. (A.) | - |
dc.creator | Salgado, A.B. (Anna Beatriz) | - |
dc.creator | García-Sanchez, O. (O.) | - |
dc.creator | Pérez-Morán, J. (José) | - |
dc.creator | Mateos, M.V. (María Victoria) | - |
dc.creator | Burgos, L. (Leire) | - |
dc.creator | Paiva, B. (Bruno) | - |
dc.creator | Marvelde, J. (Jeroen) te | - |
dc.creator | Velden, V.H.J. (Vicent H. J.) van der | - |
dc.creator | Aguilar, C. (Carlos) | - |
dc.creator | Barez, A. (A.) | - |
dc.creator | García-Mateo, A. (A.) | - |
dc.creator | Labrador, J. (Jorge) | - |
dc.creator | Leoz, P. (Pilar) | - |
dc.creator | Aguilera-Sanz, C. (Carmen) | - |
dc.creator | Durie, B. (B.) | - |
dc.creator | Dongen, J.J.M. (Jacques J. M.) van | - |
dc.creator | Maiolino, A. (Angelo) | - |
dc.creator | Sobral-da-Costa, E. (Elaine) | - |
dc.creator | Orfao, A. (Alberto) | - |
dc.creator | EuroFlow-Consortium | - |
dc.date.accessioned | 2021-08-09T09:09:09Z | - |
dc.date.available | 2021-08-09T09:09:09Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Mendonca-de-Pontes, R.; Flores-Montero, J.; Sanoja-Flores, L.; et al. "B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients". Cancers. 13 (7), 2021, 1704 | es |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://hdl.handle.net/10171/61229 | - |
dc.description.abstract | Simple Summary B-cell regeneration during therapy has been associated with the outcome of multiple myeloma (MM) patients. However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated. Here, we show that hemodilution is present in a significant fraction of MM BM samples, leading to lower total B-cell, B-cell precursor (BCP), and normal plasma cell (nPC) counts. Among MM BM samples, decreased percentages (vs. healthy donors) of BCP, transitional/naive B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP, but not TBC/NBC, increased after induction therapy. At day+100 post-autolo-gous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19(-) nPC counts vs. non-CR specimens with no clear association between BM B-cell regeneration profiles and patient outcomes. B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (>= 50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naive B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19(-) nPC counts vs. non-CR specimens. MRD positivity was associated with higher BCP and nPC percentages. Hemodilution showed a negative impact on BM B-cell distribution. Different BM B-cell regeneration profiles are present in MM at diagnosis and after therapy with no significant association with patient outcome. | - |
dc.language.iso | en | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | Multiple myeloma | - |
dc.subject | B-cell regeneration | - |
dc.subject | Hemodilution | - |
dc.subject | Measurable residual disease | - |
dc.subject | Immunophenotyping | - |
dc.title | B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients | - |
dc.type | info:eu-repo/semantics/article | - |
dc.description.note | This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/) | - |
dc.identifier.doi | 10.3390/cancers13071704 | - |
dadun.citation.number | 7 | - |
dadun.citation.publicationName | Cancers | - |
dadun.citation.startingPage | 1704 | - |
dadun.citation.volume | 13 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.